<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Long-term management of patients with anaphylaxis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Long-term management of patients with anaphylaxis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Long-term management of patients with anaphylaxis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Turner, FRCPCH, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Kelso, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H7657148"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The medical management of anaphylaxis has traditionally focused on recognition and treatment of the acute event. Equally important, however, is the long-term care of a patient who has experienced anaphylaxis and the implementation of measures to prevent and treat recurrences in community settings [<a href="#rid1">1,2</a>].</p><p>This topic will discuss the proactive, long-term management of patients after diagnosis and treatment of their acute anaphylaxis episode and confirmation of the cause(s). The diagnosis and treatment of acute anaphylaxis episode and an approach to identifying causes for anaphylaxis are discussed separately. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a> and  <a class="medical medical_review" href="/d/html/391.html" rel="external">"Anaphylaxis: Confirming the diagnosis and determining the cause(s)"</a>.) </p><p class="headingAnchor" id="H7657155"><span class="h1">ONGOING EDUCATION FOR PATIENTS</span><span class="headingEndMark"> — </span>Patients (and, for children, their families and caregivers) must be able to recognize the signs and symptoms of an anaphylaxis recurrence in the community and initiate treatment in a prompt and effective manner. Education about the recognition and management of anaphylaxis is an ongoing, long-term process that should be continued at follow-up visits with an allergy specialist at least annually while the patient remains at risk.</p><p class="headingAnchor" id="H7657162"><span class="h2">Important teaching points</span><span class="headingEndMark"> — </span>Important teaching points, which should be reviewed on a regular basis, include the following  (<a class="graphic graphic_table graphicRef51175" href="/d/graphic/51175.html" rel="external">table 1</a>) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> (adrenaline) is the first-line and most appropriate treatment for anaphylaxis; it should be given by intramuscular injection into the upper outer thigh muscle as soon as possible after symptoms of anaphylaxis are present (or if there is any doubt as to whether epinephrine is indicated) [<a href="#rid2">2-7</a>]. If a patient at risk for anaphylaxis had an epinephrine autoinjector prescribed but did not fill the prescription, did not have the autoinjector available at the time of the episode, or had it available but failed to use it, these issues should be discussed in-depth during the follow-up visit [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>H1 antihistamines and asthma inhalers (eg, <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>) alone are <strong>not</strong> adequate treatment and are often ineffective for anaphylaxis. H1 antihistamines relieve itch and hives but take approximately 30 minutes to have an effect; they are ineffective against symptoms of anaphylaxis. Similarly, asthma inhalers provide temporary relief from wheezing and coughing but do not prevent or relieve upper airway obstruction, hypotension, or shock and are therefore not lifesaving [<a href="#rid1">1-5,7,8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The severity of previous episodes of anaphylaxis does not always predict the severity of future episodes, which may be more severe, less severe, or similar to previous episodes [<a href="#rid1">1,9</a>]. However, in patients who experience recurrent anaphylaxis, the severity as well as the sequence of symptoms of subsequent episodes are most often the same as previous episodes [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anaphylaxis is underrecognized and undertreated, even by health care professionals [<a href="#rid11">11,12</a>]. Some patients do not have ready access to emergency medical services, and some emergency medical services teams are still not equipped with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> or permitted to inject it. Therefore, people at risk for anaphylaxis (and, for children, their families or caregivers) must have an epinephrine autoinjector available at all times so that effective treatment can be initiated without delay.</p><p></p><p class="headingAnchor" id="H7657169"><span class="h1">PREPARING THE PATIENT TO TREAT POSSIBLE RECURRENCES</span><span class="headingEndMark"> — </span>Patients who have experienced anaphylaxis should be equipped to treat possible recurrences in the community by carrying self-injectable <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, having an anaphylaxis emergency action plan, and wearing medical identification.</p><p class="headingAnchor" id="H7657176"><span class="h2">Self-injectable epinephrine</span><span class="headingEndMark"> — </span>Any patient who has experienced anaphylaxis should be supplied with one or more <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors and trained in why, when, and how to inject epinephrine [<a href="#rid1">1-7,13</a>]. For children who have experienced anaphylaxis, families and caregivers should be trained. Issues with regard to prescribing epinephrine autoinjectors correctly are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment"</a>.)</p><p>Patient educational materials include autoinjector trainers and printed handouts (see  <a class="medical medical_patient" href="/d/html/365.html" rel="external">"Patient education: Using an epinephrine autoinjector (Beyond the Basics)"</a>). Most autoinjector manufacturers provide trainer devices and website videos for training purposes.</p><p>Important issues with regard to <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> injection include need for prompt administration [<a href="#rid14">14</a>], need for a second dose [<a href="#rid15">15</a>], inability of children to access their epinephrine autoinjectors in school [<a href="#rid16">16</a>], lack of availability and/or high cost of autoinjectors in many countries [<a href="#rid17">17</a>], and need for training and regular coaching in correct and safe use of autoinjectors [<a href="#rid18">18</a>]. </p><p class="headingAnchor" id="H2989890897"><span class="h3">Important issues for discussion</span><span class="headingEndMark"> — </span>There are some important reasons why a patient (or, for children, their families and caregivers) may fail to administer <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> when it is appropriate to do so. Providers should address these issues directly with patients as appropriate.</p><p class="bulletIndent1"><span class="glyph">●</span>One study surveyed a unique population of 1885 survivors of anaphylaxis in the community and asked about administration of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid19">19</a>]. Users of epinephrine autoinjectors were defined as those who self-injected epinephrine or injected it into a person for whom they were responsible (eg, a child) during anaphylaxis. Users reported problems in deciding whether to use the epinephrine autoinjector, whether to go to the emergency department after using it, holding it in place, choosing the correct site on the thigh for the injection, deciding whether to repeat the dose, and disposing of the autoinjector(s) after use. Nonusers were defined as those who did not self-inject epinephrine or failed to inject it into a person for whom they were responsible (eg, a child) during anaphylaxis. Nonusers reported a variety of reasons for not injecting epinephrine, such as using an H1 antihistamine or an asthma inhaler instead and/or not having the epinephrine autoinjector available when the medical emergency occurred [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of children who had experienced anaphylaxis, caregivers' reasons for not using an <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjector included the belief that it was unnecessary (54.4 percent), uncertainty about its necessity (19.1 percent), having called an ambulance (7.8 percent), not having the device available (5.4 percent), fear of using it (2.5 percent), lack of training (2.5 percent), decision to go to the emergency department (1.5 percent), and expired device (1 percent) [<a href="#rid20">20</a>]. The use of expired autoinjectors is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment", section on 'Use of expired autoinjectors'</a>.)</p><p></p><p>Educational efforts should focus on reviewing the following with patients and caregivers: the circumstances under which the autoinjector should be used, the importance of using it even if they have already called an ambulance or are headed to the emergency department, using it even if it is out of date, and having the device available at all times. Providers should repeatedly train patients and caregivers. Patients/caregivers can increase their comfort with the device by practicing with a trainer on themselves/the child and by practicing with expired live devices (once replaced) by injecting an orange. Some health care professionals have advocated for "practice" injections using nearly expired devices or a needle/syringe [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H7657183"><span class="h2">Anaphylaxis emergency action plan</span><span class="headingEndMark"> — </span>Any individual who is at risk of anaphylaxis should have a written, personalized, and regularly updated anaphylaxis emergency action plan, developed with the assistance of their health care professional. In order to help patients recognize anaphylaxis, this form should list typical symptoms and signs that might develop suddenly during an episode. In addition, it should provide instructions for prompt <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> injection followed by transportation to the nearest hospital emergency department.</p><p>Action plan forms are available in English and Spanish from Food Allergy Research and Education (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.foodallergy.org%2Fliving-food-allergies%2Ffood-allergy-essentials%2Ffood-allergy-anaphylaxis-emergency-care-plan&amp;token=NNxgipojDjc6eUqFyNKHcsvyAY%2FDx4jKyTcliMcI%2FOPaQ%2FjzEF7N9k2soYiG8mShsTzbyYs9rS2vILAP7FvxJpIKTyqQHjaRSxmcKUc2r50QIVHycnld4%2FlwOD8ZIsNl&amp;TOPIC_ID=15817" target="_blank">Food Allergy &amp; Anaphylaxis Emergency Care Plan</a>) and the American Academy of Pediatrics (Allergy and Anaphylaxis Emergency Plan: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdownloads.aap.org%2FHC%2FAAP_Allergy_and_Anaphylaxis_Emergency_Plan.pdf&amp;token=4tUdim4kUUoEdF4xVqZyP1OZTYl5ynY7AcHvKTQc%2FyAlW1gfEYywJe2Z60BkorM1cuqDab6aKTMWJBQDiSsxIZreD157OtS3QcR7YRl1Sqs%3D&amp;TOPIC_ID=15817" target="_blank">English</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdownloads.aap.org%2FAAP%2FPDF%2FAAEP.Spanish.PDF.rm.1.26.21.pdf&amp;token=9%2B1WzAVoaNG6j5eyEhahpHc1cwEf8kiZnKp7PO1zDLh4a4oPljbonLaJHSwCq6B2Ingi51OHSyB%2FzpnaDg%2BUjKPtp%2B8L%2FE%2BEmSzWGUhTfko%3D&amp;TOPIC_ID=15817" target="_blank">Spanish</a>). Other organizations across the world also provide their own plans, such as in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bsaci.org%2Fprofessional-resources%2Fresources%2Fpaediatric-allergy-action-plans%2F&amp;token=ViwJPEItCKcULywLqYaI2Ab1qHHarBBt0l59BYETc4fkAgweDxe7RuQaTESfsPCEQkOMd%2B2%2FpMt%2B%2BjwZLC8sTwKPoQGCCWH7YSyDUCHHSmE%3D&amp;TOPIC_ID=15817" target="_blank">United Kingdom</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.allergy.org.au%2Fhp%2Fanaphylaxis%2Fascia-action-plan-for-anaphylaxis&amp;token=G29WNByNh87jeKdghGZCZqYSBA5Ve1112D2dUtIxwXWUgfZo1STEo%2BqIcDgEqOZwgCFsWsuuNEASQpL0GKGgcKkAiSg7ILK70VPj3lNCsqQ%3D&amp;TOPIC_ID=15817" target="_blank">Australia/New Zealand</a>. These plans are appropriate for patients with anaphylaxis from any cause. (See <a class="local">'Internet resources'</a> below.)</p><p>Multiple copies of the completed form should be available at home, work, or school and when discussing the information with anyone who may be responsible for administering <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> to the patient at risk of anaphylaxis recurrence. In addition, the written personalized anaphylaxis emergency action plan should be reviewed and updated periodically at follow-up visits. This process often reveals areas in which the patient needs further instruction and also stimulates discussion of more complex and patient-specific issues [<a href="#rid2">2</a>].</p><p><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.aaaai.org%2FAaaai%2Fmedia%2FMediaLibrary%2FPDF+Documents%2FLibraries%2FAnaphylaxis-Card.pdf&amp;token=Py6IaQmoqUBqjXL3OMmoExyYxpjs7fi04iG637wia%2BAWKpR%2FgoqSD4AuPsKhj%2FLpWJJ900QGWWMbcQdCM7kwDMrZyJwwTc2z9is7r9hNl3hnnFZwx1FuCme5qzUAuyxN&amp;TOPIC_ID=15817" target="_blank">Anaphylaxis wallet cards</a> are also available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aaaai.org%2F&amp;token=RxBqIaK4IjVvTPMpPUJnutMMeVmA8xmPyYsKJbu1ibM%3D&amp;TOPIC_ID=15817" target="_blank">AAAAI</a> [<a href="#rid2">2</a>]. These cards contain similar information to the information on the anaphylaxis emergency action plan. Data from a randomized, controlled trial indicate that they are practical, concise anaphylaxis education mini-handouts [<a href="#rid22">22</a>].</p><p>Formal evaluation of the clinical efficacy and cost effectiveness of anaphylaxis emergency action plans is needed [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H7657190"><span class="h2">Medical identification</span><span class="headingEndMark"> — </span>Patients should also be advised to consider medical identification jewelry listing the known causes for their anaphylaxis and their relevant comorbidities and concurrent medications. Options include medical identification bracelets and medallions. Bracelets are deemed safest for children to wear.</p><p>Detailed information about the known causes for a patient's anaphylaxis should be accurately documented in an individual's electronic and/or paper medical records and updated as needed [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H7657197"><span class="h1">DETECTION AND MANAGEMENT OF COMORBIDITIES</span><span class="headingEndMark"> — </span>Coexistent medical conditions and medications that could impact the ability of the patient to withstand anaphylaxis or respond to <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> should be explored in all patients who have experienced anaphylaxis.</p><p class="headingAnchor" id="H89977197"><span class="h2">Comorbidities</span></p><p class="headingAnchor" id="H1028604644"><span class="h3">Asthma</span><span class="headingEndMark"> — </span>Persistent asthma, especially if symptoms are poorly controlled, may be an important risk factor for more severe anaphylaxis [<a href="#rid23">23</a>]. Optimal asthma management is therefore critically important in those patients with asthma who are also at risk of anaphylaxis to reduce morbidity from asthma and possibly anaphylaxis. (See  <a class="medical medical_review" href="/d/html/390.html" rel="external">"Fatal anaphylaxis", section on 'Possible risk factors'</a>.)</p><p class="headingAnchor" id="H1456754899"><span class="h3">Cardiovascular disease</span><span class="headingEndMark"> — </span>Cardiovascular disease may be an important risk factor for deaths from anaphylaxis in middle-aged and older patients [<a href="#rid24">24,25</a>]. These risks need to be discussed with the patient as needed and with the other health care professionals involved in the patient's care. (See  <a class="medical medical_review" href="/d/html/390.html" rel="external">"Fatal anaphylaxis", section on 'Possible risk factors'</a>.)</p><p class="headingAnchor" id="H1567842396"><span class="h3">Mast cell disorders</span><span class="headingEndMark"> — </span>Individuals with idiopathic anaphylaxis or severe anaphylaxis, particularly in response to insect stings, should be screened for underlying mast cell disease, such as indolent systemic mastocytosis. In contrast, there is no good evidence that underlying mast cell disease is a risk factor in severe anaphylaxis due to food allergy. Note that individuals with indolent mastocytosis can have a normal serum baseline tryptase level and no cutaneous or systemic findings such as organomegaly [<a href="#rid26">26</a>]. Such patients may be identified through mutational assays using D816V allele-specific polymerase chain reaction (PCR) primers (allele-specific quantitative PCR), performed on peripheral blood. (See  <a class="medical medical_review" href="/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H175699002"><span class="h3">Hereditary alpha tryptasemia</span><span class="headingEndMark"> — </span>Hereditary alpha tryptasemia (HaT) is a common, autosomal dominant genetic trait, first recognized in 2016, which affects 5 to 6 percent of White populations in the United States, and Europe. Other populations have not yet been studied. The majority of individuals with HaT appear to be asymptomatic. In symptomatic patients, the presence of HaT is associated with an increased frequency and severity of immediate hypersensitivity reactions in at least three disorders: systemic mastocytosis, Hymenoptera venom allergy (ie, allergy to the stings of bees and related insects), and idiopathic anaphylaxis. (See  <a class="medical medical_review" href="/d/html/135236.html" rel="external">"Hereditary alpha-tryptasemia"</a>.)</p><p class="headingAnchor" id="H7657204"><span class="h2">Medications for other disorders</span><span class="headingEndMark"> — </span>The long-term management of patients with anaphylaxis also involves discussion of medications taken concomitantly for other disorders. The following classes of medications potentially present problems for patients at risk for recurrence of anaphylaxis:</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-adrenergic blockers administered orally or topically (eg, eye drops) may be associated with severe anaphylaxis and may also potentially make anaphylaxis more difficult to treat by causing unopposed alpha-adrenergic effects and hypertension and reduced bronchodilator response to the beta-adrenergic effects of endogenous or exogenous <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid7">7,27</a>]. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment", section on 'Glucagon for patients taking beta blockers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alpha-adrenergic blockers may decrease the effects of endogenous or exogenous <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> at alpha-adrenergic receptors, rendering patients less responsive to the alpha-adrenergic effects of epinephrine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin-converting enzyme (ACE) inhibitors may interfere with endogenous compensatory mechanisms, resulting in more severe or prolonged symptoms [<a href="#rid27">27,28</a>]. ACE inhibitors in combination with beta blockers may increase risk synergistically. Angiotensin II receptor blockers might be less likely to have this effect, although this has not been conclusively documented [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) active medications, such as psychotropics, anxiolytics, and insomnia remedies, may impair cognitive function and patients' ability to recognize anaphylaxis causes and symptoms. CNS-active medications include sedating, first-generation H1 antihistamines (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>), which are widely used for the treatment of insomnia and allergic diseases [<a href="#rid2">2,3,5,8</a>].</p><p></p><p>The relevant risks and benefits of medications in the above classes should be discussed with these patients and with other health care professionals involved in their care, as the benefits of ongoing prescription may outweigh the risks of anaphylaxis. These discussions should be documented in the patient's medical record. Substitution of medications may be necessary in some patients.</p><p class="headingAnchor" id="H7657211"><span class="h1">EFFECTIVE AVOIDANCE OF TRIGGERS</span><span class="headingEndMark"> — </span>Complete avoidance of an allergen requires ongoing education about the allergen and where it is likely to be encountered. Printed information on avoidance of relevant, specific allergens should be provided and reviewed at regular intervals with those at risk and their families and caregivers [<a href="#rid1">1,2,7</a>].</p><p class="headingAnchor" id="H1842972169"><span class="h2">Allergens</span><span class="headingEndMark"> — </span>The most common allergens are mentioned here. However, the list of implicated substances continues to lengthen  (<a class="graphic graphic_table graphicRef70667" href="/d/graphic/70667.html" rel="external">table 2</a>). The cause of a patient's anaphylaxis is determined by taking a meticulous history and confirming the suspected culprit(s) by allergen-specific skin tests and allergen-specific immunoglobulin E (IgE) levels in serum. This is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/391.html" rel="external">"Anaphylaxis: Confirming the diagnosis and determining the cause(s)", section on 'Testing for allergen cause(s)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food</strong> – Patients with a history of food-induced anaphylaxis should avoid the foods that cause the reaction [<a href="#rid30">30,31</a>]. This is easier said than done [<a href="#rid32">32</a>]. Difficulties arise because of hidden, substituted, and cross-reacting foods, as well as foods that are contaminated with allergen because of cross-contact, for example, on shared production lines or in catering kitchens. Food producers often use "advisory" or "precautionary" allergen statements (such as "may contain X") to communicate risk; unfortunately, such statements are currently unregulated and may not accurately communicate the true presence or absence of unintended low-level allergen contamination in food products [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Vigilant food avoidance measures potentially decrease quality of life for those at risk of anaphylaxis to food and their families and for children, their caregivers, teachers, childcare workers, and classmates [<a href="#rid34">34,35</a>]. Adolescents and young adults at risk for food-induced anaphylaxis are particularly prone to risk-taking behaviors [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/2411.html" rel="external">"Food allergy: Impact on health-related quality of life"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insect stings</strong> – Ideally, patients with a history of insect sting-induced anaphylaxis should avoid subsequent exposure to insects. However, this is impractical under many circumstances and may be impossible for beekeepers, park rangers, gardeners, and others with occupational exposure [<a href="#rid7">7,37</a>]. (See  <a class="medical medical_review" href="/d/html/4094.html" rel="external">"Stinging insects: Avoidance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Patients with a history of anaphylaxis to a medication or biologic agent should have this clearly documented in the allergies section of their medical record and must not be given that specific medication. A safe and effective non-cross-reacting drug, preferably from a different pharmacologic class, should be substituted, if available. A written list containing the name of the medication that caused the anaphylaxis and the names of related and cross-reacting drugs should be provided [<a href="#rid5">5,7,38-40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccines – </strong>Anaphylaxis to vaccines for prevention of infectious diseases is rare [<a href="#rid41">41</a>], even to vaccines introduced during the coronavirus disease 2019 (COVID-19) pandemic (see  <a class="medical medical_review" href="/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Immediate-type hypersensitivity reactions'</a>). Patients with this history may be evaluated by using skin tests to the vaccine and its components (excipients) [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/2074.html" rel="external">"Allergic reactions to vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise</strong> – Prevention strategies for anaphylaxis caused by exercise depend upon the avoidance of cofactors, including potential trigger foods, ethanol, or specific medications (eg, nonsteroidal antiinflammatory drugs [NSAIDs]). Where reactions are triggered by a food in combination with a cofactor, empirical advice is for the food to be avoided for approximately four hours before exercise. If no specific cofactor for exercise-induced anaphylaxis has been identified, it might be prudent for the individual to avoid ingesting anything at all within four hours of exercise. Factors amplifying exercise-induced anaphylaxis might include airborne pollen or mold allergens, high humidity, extreme heat, or extreme cold. Based on a detailed history of the patient's previous episodes, avoidance of one or more of these factors might be relevant. People with exercise-induced anaphylaxis need to be advised that they should not exercise alone. They should discontinue exercise at the earliest hint of symptom development and inject <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>. They should not run for help [<a href="#rid7">7,42</a>]. (See  <a class="medical medical_review" href="/d/html/385.html" rel="external">"Exercise-induced anaphylaxis: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural rubber latex (NRL)</strong> – Patients at risk for anaphylaxis from NRL should avoid exposure to NRL, which can be found in disposable gloves, condoms, infant pacifiers, toys, balloons, sports equipment, and other items. They should inform all of their health care professionals about their NRL allergy, particularly when being evaluated for potential surgery or dental work. In some of these patients, foods that cross-react with NRL (for example, kiwi, banana, avocado, tomato, and white potato) should also be avoided [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/5554.html" rel="external">"Latex allergy: Management", section on 'Individual avoidance'</a> and  <a class="medical medical_review" href="/d/html/2403.html" rel="external">"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)", section on 'Latex-fruit syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H21909997"><span class="h2">Cofactors</span><span class="headingEndMark"> — </span>Many patients develop symptoms more readily in the presence of one or more additional cofactors or augmenting factors. The cofactors that are relevant for any given patient vary considerably, but may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Exercise, physical exertion</p><p class="bulletIndent1"><span class="glyph">●</span>Stress or jet lag</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal antiinflammatory drugs (NSAIDs)</p><p class="bulletIndent1"><span class="glyph">●</span>Alcoholic beverages</p><p class="bulletIndent1"><span class="glyph">●</span>Premenstrual or ovulatory phases of the menstrual cycle</p><p class="bulletIndent1"><span class="glyph">●</span>Extremes of temperature (either high heat and humidity or cold exposure)</p><p class="bulletIndent1"><span class="glyph">●</span>Seasonal pollen exposure in pollen-sensitized patients</p><p class="bulletIndent1"><span class="glyph">●</span>Infections or illness</p><p></p><p class="headingAnchor" id="H7657218"><span class="h1">INTERVENTIONS TO REDUCE SENSITIVITY</span><span class="headingEndMark"> — </span>Specific interventions to reduce the risk of recurrent reactions are available for certain causes of anaphylaxis [<a href="#rid37">37-44</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food</strong> – Immunotherapy for individuals at risk of food-induced anaphylaxis is becoming increasingly available in many countries [<a href="#rid45">45,46</a>], and a treatment for peanut allergy has been approved by the US Food and Drug Administration (FDA), although uptake has been limited [<a href="#rid47">47</a>]. Immunotherapy is typically performed through oral exposure ("oral immunotherapy"), although the sublingual and epicutaneous (skin patch) routes have also been evaluated; the latter has been shown to be efficacious as well, but an approved product is not yet available. Desensitization (temporary antigen hyporesponsiveness that depends on regular food ingestion) is successful in approximately 60 percent of individuals but is often lost after a period of avoidance. Permanent immunologic tolerance (the ability to ingest food without symptoms despite prolonged periods of avoidance or irregular intake) has been difficult to demonstrate, but several studies have shown that this can now be achieved in approximately 30 percent of subjects with longer durations of treatment (three to five years) prior to avoidance [<a href="#rid48">48</a>]. Treatment-related symptoms are common, as is anaphylaxis [<a href="#rid49">49,50</a>]. Alternative approaches are undergoing clinical trials, including vaccines for food allergy and also the use of monoclonal antibodies such as anti-IgE therapies, both of which also have shown promising results in preliminary studies [<a href="#rid51">51,52</a>]. (See  <a class="medical medical_review" href="/d/html/113421.html" rel="external">"Oral immunotherapy for food allergy"</a> and  <a class="medical medical_review" href="/d/html/2410.html" rel="external">"Experimental therapies for food allergy: Immunotherapy and nonspecific therapies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insect stings</strong> – Anaphylaxis caused by venom from insects in the order Hymenoptera (eg, honey bees, yellowjackets, yellow hornets, white-faced hornets, paper wasps, and fire ants) can be almost entirely prevented by use of allergen-specific immunotherapy, as demonstrated in randomized, placebo-controlled trials. This therapy is initiated by an allergy/immunology specialist. A five-year treatment period provides long-lasting protection for most patients, although, in some high-risk patients (such as those with underlying systemic mastocytosis), it is continued indefinitely [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/4090.html" rel="external">"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action", section on 'Indications and patient selection'</a> and  <a class="medical medical_review" href="/d/html/4092.html" rel="external">"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment", section on 'Venom immunotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications needed daily</strong> – Anaphylaxis may be caused by a medication that is essential for the patient and is needed on a daily basis and for which there is no effective and safe substitute available (eg, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for the patient with atherosclerotic heart disease). Successful desensitization must be followed by regular daily administration; otherwise, the desensitization effect is lost [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions"</a> and  <a class="medical medical_review" href="/d/html/2085.html" rel="external">"Diagnostic challenge and desensitization protocols for NSAID reactions"</a> and  <a class="medical medical_review" href="/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications needed temporarily</strong> – Desensitization can be performed successfully to prevent anaphylaxis caused by a drug that is needed temporarily as a single dose or an uninterrupted course of multiple doses and for which there is no effective and safe substitute available. Examples include antimicrobials, especially beta-lactam antibiotics, antifungals, antivirals, nonsteroidal antiinflammatory drugs (NSAIDs), chemotherapeutics (eg, platinum salts and taxanes), and biologics [<a href="#rid38">38,39</a>]. It is important to counsel the individual that the desensitization effect only persists for as long as the treatment is taken. Even just a break of a few days is sufficient to cause the patient to be reactive, and, if the medication is subsequently needed again, then the patient must undergo further desensitization. (See  <a class="medical medical_review" href="/d/html/2071.html" rel="external">"Rapid drug desensitization for immediate hypersensitivity reactions"</a> and  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human seminal fluid</strong> – Uncommonly, seminal fluid can cause anaphylaxis in females. Symptoms typically begin during or shortly after sexual intercourse. Reactions to seminal fluid can be prevented by use of condoms. Desensitization strategies have been described [<a href="#rid7">7,44</a>]. (See  <a class="medical medical_review" href="/d/html/13529.html" rel="external">"Allergic reactions to seminal plasma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic anaphylaxis</strong> – Idiopathic anaphylaxis is a diagnosis of exclusion that is made when no cause for the anaphylaxis episode can be identified. Some patients with this diagnosis actually have a mast cell disorder. Therefore, in addition to a meticulous history and physical examination for skin lesions of cutaneous mastocytosis, an elevated baseline serum tryptase level may help to identify such patients [<a href="#rid28">28,53,54</a>]. <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">Omalizumab</a>, a monoclonal antibody to IgE, may also provide some protection. (See  <a class="medical medical_review" href="/d/html/387.html" rel="external">"Idiopathic anaphylaxis"</a> and  <a class="medical medical_review" href="/d/html/15715.html" rel="external">"Mast cell disorders: An overview"</a>.)</p><p></p><p class="headingAnchor" id="H7657225"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>The long-term monitoring of a patient with a history of anaphylaxis due to a known cause includes following the status of the individual's sensitization to the allergen over time.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food allergy</strong> – For patients with food-induced anaphylaxis, appropriate monitoring involves obtaining detailed historical information about inadvertent exposures and reactions, as well as measurements of food-specific IgE levels in serum or, less commonly, food-specific skin tests at appropriate intervals, depending on their age and thus likelihood of natural resolution or outgrowth: Most children allergic to cow's milk and hen's egg will outgrow this allergy over time, while only a minority that are allergic to peanuts and tree nuts will do so [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/5745.html" rel="external">"Food allergy in children: Prevalence, natural history, and monitoring for resolution"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug allergies</strong> – For patients with drug-induced anaphylaxis, monitoring of sensitization status is also important, as sensitization may resolve with sufficient time. As an example, only a small percentage of patients labeled as penicillin allergic are actually allergic. Skin testing and challenge consistently demonstrate that the vast majority can safely receive penicillin [<a href="#rid56">56</a>], although, increasingly, approaches to delabeling no longer recommend skin testing prior to oral challenge in low-risk individuals [<a href="#rid57">57,58</a>]. (See  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a>.)</p><p></p><p class="headingAnchor" id="H7657239"><span class="h1">INTERNET RESOURCES</span><span class="headingEndMark"> — </span>There are a number of internet resources available for patients that consistently provide accurate information, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.foodallergy.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5XowUrwo9JF1Bee2tadnAs8nOz4ixcAr6ReEsd5sotUp&amp;TOPIC_ID=15817" target="_blank">Food Allergy Research &amp; Education (FARE)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aaaai.org%2F&amp;token=RxBqIaK4IjVvTPMpPUJnutMMeVmA8xmPyYsKJbu1ibM%3D&amp;TOPIC_ID=15817" target="_blank">American Academy of Allergy, Asthma &amp; Immunology (AAAAI)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Facaai.org%2F&amp;token=tZrUlmu6F5AD6Dd2hqyGsjeNIy2IZFShjUghjy6nBrI%3D&amp;TOPIC_ID=15817" target="_blank">American College of Allergy, Asthma &amp; Immunology (ACAAI)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.niaid.nih.gov%2F&amp;token=lblfowwGB6QwC91WNuiIf%2FQyg%2BQCRCT4lKIYofMztqKvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=15817" target="_blank">National Institute of Allergy and Infectious Diseases (NIAID)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.csaci.ca%2Fpatient-school-resources%2F&amp;token=f3DNIdk%2F1lHIhjgNfsAlD25ZLCS3K2veKT3FQkycZ%2FW%2FWFSu5RRV3wOc5PEybdwzjbzbTd1RG5pQA%2BQXqeY%2BUw%3D%3D&amp;TOPIC_ID=15817" target="_blank">Canadian Society of Allergy and Clinical Immunology (CSACI)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bsaci.org%2F&amp;token=wkK3meDdGl8H0MjoHsM%2FRyEbww126nJzQy2eENnE9e0%3D&amp;TOPIC_ID=15817" target="_blank">British Society for Allergy &amp; Clinical Immunology (BSACI)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhub.eaaci.org%2Fpatients%2F&amp;token=bfWTGwx8t186kDcmkg04hUhB5P5afg08QEzaze9BOTlEJqrpwRPSwg7b6O6trf%2FR&amp;TOPIC_ID=15817" target="_blank">European Academy of Allergy and Clinical Immunology (EAACI)</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.allergy.org.au%2F&amp;token=%2BCjrhIBVW0jZK35njTvgcdHs6wGsm0fPdl2slJy2GWAJCn9k3YrnRE9Zn5Kcxgc1&amp;TOPIC_ID=15817" target="_blank">Australasian Society of Clinical Immunology and Allergy (ASCIA</a>)</p><p></p><p class="headingAnchor" id="H3640210261"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105526.html" rel="external">"Society guideline links: Anaphylaxis"</a>.)</p><p class="headingAnchor" id="H21717519"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15336.html" rel="external">"Patient education: Anaphylaxis (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15917.html" rel="external">"Patient education: How to use an epinephrine autoinjector (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/368.html" rel="external">"Patient education: Anaphylaxis symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/372.html" rel="external">"Patient education: Anaphylaxis treatment and prevention of recurrences (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/365.html" rel="external">"Patient education: Using an epinephrine autoinjector (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H7657253"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing education </strong>– Patients (and, for children, their families and caregivers) should be taught to recognize the early symptoms of anaphylaxis and to inject <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> promptly  (<a class="graphic graphic_table graphicRef51175" href="/d/graphic/51175.html" rel="external">table 1</a>). They should be counseled regularly that epinephrine injection is the only appropriate emergency treatment for anaphylaxis. For patients with confirmed anaphylaxis, evaluation to determine the responsible trigger and education about specific allergen avoidance are essential. This is an ongoing, long-term process that should be continued at each follow-up visit. (See <a class="local">'Ongoing education for patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Training in use of an </strong><a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a><strong> autoinjector </strong>– Patients should be supplied with at least one and preferably two doses of epinephrine autoinjector devices and trained in when and how to use the autoinjector (See <a class="local">'Preparing the patient to treat possible recurrences'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anaphylaxis action plan </strong>– A personalized anaphylaxis emergency action plan is a written, one-page document that lists the signs and symptoms of anaphylaxis and outlines treatment appropriate for that individual. It can be used to convey information between clinician and patient, as well as between patient and family, caregivers, teachers, or other people who may be involved in emergency treatment of recurrent episodes. (See <a class="local">'Anaphylaxis emergency action plan'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Review of medications for other disorders </strong>– All prescription and nonprescription medications taken by the patient for any reason should be monitored. Certain medications may interfere with early recognition of symptoms, increase the severity of symptoms, or impact the treatment of anaphylaxis. In some clinical situations, it is possible to substitute medications with a more favorable benefit:risk ratio. (See <a class="local">'Medications for other disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Education about allergen avoidance </strong>– Avoidance of triggers for anaphylaxis is easier said than done and is difficult to maintain over years or decades. However, it is of fundamental importance in prevention of subsequent anaphylaxis in the community. (See <a class="local">'Effective avoidance of triggers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interventions to reduce sensitivity to specific allergens </strong>– Specific immunomodulation is available for patients with anaphylaxis caused by certain causes, such as stinging insect venoms, certain foods, and some medications. (See <a class="local">'Interventions to reduce sensitivity'</a> above.)</p><p></p><p class="headingAnchor" id="H224272695"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges F Estelle R Simons, MD, FRCPC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.</a></li><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.</a></li><li><a class="nounderline abstract_t">Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation 2008; 77:157.</a></li><li><a class="nounderline abstract_t">Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. Med J Aust 2006; 185:283.</a></li><li><a class="nounderline abstract_t">Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587.</a></li><li><a class="nounderline abstract_t">Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10:354.</a></li><li><a class="nounderline abstract_t">Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082.</a></li><li><a class="nounderline abstract_t">Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62:830.</a></li><li><a class="nounderline abstract_t">Simons FE, Sampson HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol 2008; 122:1166.</a></li><li><a class="nounderline abstract_t">Slapnicar C, Lebovic G, McParland A, et al. Reproducibility of Symptom Sequences Across Episodes of Recurrent Anaphylaxis. J Allergy Clin Immunol Pract 2022; 10:534.</a></li><li><a class="nounderline abstract_t">Gaeta TJ, Clark S, Pelletier AJ, Camargo CA. National study of US emergency department visits for acute allergic reactions, 1993 to 2004. Ann Allergy Asthma Immunol 2007; 98:360.</a></li><li><a class="nounderline abstract_t">Jacobsen RC, Toy S, Bonham AJ, et al. Anaphylaxis knowledge among paramedics: results of a national survey. Prehosp Emerg Care 2012; 16:527.</a></li><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.</a></li><li><a class="nounderline abstract_t">Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.</a></li><li><a class="nounderline abstract_t">Manivannan V, Campbell RL, Bellolio MF, et al. Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009; 103:395.</a></li><li><a class="nounderline abstract_t">Ben-Shoshan M, Kagan R, Primeau MN, et al. Availability of the epinephrine autoinjector at school in children with peanut allergy. Ann Allergy Asthma Immunol 2008; 100:570.</a></li><li><a class="nounderline abstract_t">Simons FE, World Allergy Organization. Epinephrine auto-injectors: first-aid treatment still out of reach for many at risk of anaphylaxis in the community. Ann Allergy Asthma Immunol 2009; 102:403.</a></li><li><a class="nounderline abstract_t">Simons FE, Edwards ES, Read EJ Jr, et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010; 125:419.</a></li><li><a class="nounderline abstract_t">Simons FE, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009; 124:301.</a></li><li><a class="nounderline abstract_t">Noimark L, Wales J, Du Toit G, et al. The use of adrenaline autoinjectors by children and teenagers. Clin Exp Allergy 2012; 42:284.</a></li><li><a class="nounderline abstract_t">Shemesh E, D'Urso C, Knight C, et al. Food-Allergic Adolescents at Risk for Anaphylaxis: A Randomized Controlled Study of Supervised Injection to Improve Comfort with Epinephrine Self-Injection. J Allergy Clin Immunol Pract 2017; 5:391.</a></li><li><a class="nounderline abstract_t">Hernandez-Trujillo V, Simons FER. Prospective evaluation of an anaphylaxis education mini-handout: the AAAAI anaphylaxis wallet card. J Allergy Clin Immunol: In Practice 2013; 1:181.</a></li><li><a class="nounderline abstract_t">González-Pérez A, Aponte Z, Vidaurre CF, Rodríguez LA. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. J Allergy Clin Immunol 2010; 125:1098.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252.</a></li><li><a class="nounderline abstract_t">Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.</a></li><li><a class="nounderline abstract_t">Kačar M, Rijavec M, Šelb J, Korošec P. Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis. Clin Exp Allergy 2023; 53:392.</a></li><li><a class="nounderline abstract_t">Lee S, Hess EP, Nestler DM, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 2013; 131:1103.</a></li><li><a class="nounderline abstract_t">Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.</a></li><li><a class="nounderline abstract_t">Caviglia AG, Passalacqua G, Senna G. Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J Allergy Clin Immunol 2010; 125:1171; author reply 1171.</a></li><li><a class="nounderline abstract_t">Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 2014; 133:291.</a></li><li><a class="nounderline abstract_t">NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.</a></li><li><a class="nounderline abstract_t">Boyano-Martínez T, García-Ara C, Pedrosa M, et al. Accidental allergic reactions in children allergic to cow's milk proteins. J Allergy Clin Immunol 2009; 123:883.</a></li><li><a class="nounderline abstract_t">La Vieille S, Hourihane JO, Baumert JL. Precautionary Allergen Labeling: What Advice Is Available for Health Care Professionals, Allergists, and Allergic Consumers? J Allergy Clin Immunol Pract 2023; 11:977.</a></li><li><a class="nounderline abstract_t">Lebovidge JS, Strauch H, Kalish LA, Schneider LC. Assessment of psychological distress among children and adolescents with food allergy. J Allergy Clin Immunol 2009; 124:1282.</a></li><li><a class="nounderline abstract_t">King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. Allergy 2009; 64:461.</a></li><li><a class="nounderline abstract_t">Greenhawt MJ, Singer AM, Baptist AP. Food allergy and food allergy attitudes among college students. J Allergy Clin Immunol 2009; 124:323.</a></li><li><a class="nounderline abstract_t">Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol 2017; 118:28.</a></li><li><a class="nounderline abstract_t">Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol 2010; 125:S126.</a></li><li><a class="nounderline abstract_t">Hong DI, Dioun AF. Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. J Allergy Clin Immunol Pract 2014; 2:13.</a></li><li><a class="nounderline abstract_t">Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.</a></li><li><a class="nounderline abstract_t">Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012; 130:25.</a></li><li><a class="nounderline abstract_t">Du Toit G. Food-dependent exercise-induced anaphylaxis in childhood. Pediatr Allergy Immunol 2007; 18:455.</a></li><li><a class="nounderline abstract_t">Wood RA. Food allergen immunotherapy: Current status and prospects for the future. J Allergy Clin Immunol 2016; 137:973.</a></li><li><a class="nounderline abstract_t">Sublett JW, Bernstein JA. Seminal plasma hypersensitivity reactions: an updated review. Mt Sinai J Med 2011; 78:803.</a></li><li><a class="nounderline abstract_t">Turner PJ, Tang MLK, Wood RA. Food Allergy and Eosinophilic Gastrointestinal Diseases-The Next 10 Years. J Allergy Clin Immunol Pract 2023; 11:72.</a></li><li><a class="nounderline abstract_t">Duca B, Patel N, Turner PJ. GRADE-ing the Benefit/Risk Equation in Food Immunotherapy. Curr Allergy Asthma Rep 2019; 19:30.</a></li><li><a class="nounderline abstract_t">Patrawala S, Ramsey A, Capucilli P, et al. Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia. J Allergy Clin Immunol Pract 2022; 10:1120.</a></li><li><a class="nounderline abstract_t">Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2019; 394:1437.</a></li><li><a class="nounderline abstract_t">Gernez Y, Nowak-Węgrzyn A. Immunotherapy for Food Allergy: Are We There Yet? J Allergy Clin Immunol Pract 2017; 5:250.</a></li><li><a class="nounderline abstract_t">Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019; 393:2222.</a></li><li><a class="nounderline abstract_t">de Silva D, Singh C, Arasi S, et al. Systematic review of monotherapy with biologicals for children and adults with IgE-mediated food allergy. Clin Transl Allergy 2022; 12:e12123.</a></li><li><a class="nounderline abstract_t">Sobczak JM, Krenger PS, Storni F, et al. The next generation virus-like particle platform for the treatment of peanut allergy. Allergy 2023; 78:1980.</a></li><li><a class="nounderline abstract_t">Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med 2015; 373:163.</a></li><li><a class="nounderline abstract_t">Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017; 140:349.</a></li><li><a class="nounderline abstract_t">Savage J, Sicherer S, Wood R. The Natural History of Food Allergy. J Allergy Clin Immunol Pract 2016; 4:196.</a></li><li><a class="nounderline abstract_t">Penicillin Allergy in Antibiotic Resistance Workgroup. Penicillin Allergy Testing Should Be Performed Routinely in Patients with Self-Reported Penicillin Allergy. J Allergy Clin Immunol Pract 2017; 5:333.</a></li><li><a class="nounderline abstract_t">Srisuwatchari W, Phinyo P, Chiriac AM, et al. The Safety of the Direct Drug Provocation Test in Beta-Lactam Hypersensitivity in Children: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract 2023; 11:506.</a></li><li><a class="nounderline abstract_t">Samarakoon U, Accarino J, Wurcel AG, et al. Penicillin allergy delabeling: Opportunities for implementation and dissemination. Ann Allergy Asthma Immunol 2023; 130:554.</a></li></ol></div><div id="topicVersionRevision">Topic 15817 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176258" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461138" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anaphylaxis, killer allergy: long-term management in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18358585" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Emergency treatment of anaphylactic reactions--guidelines for healthcare providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16948628" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Anaphylaxis: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21377030" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : World Allergy Organization anaphylaxis guidelines: summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543673" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epinephrine and its use in anaphylaxis: current issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001253" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620060" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19084110" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anaphylaxis epidemic: fact or fiction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34933152" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reproducibility of Symptom Sequences Across Episodes of Recurrent Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17458433" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : National study of US emergency department visits for acute allergic reactions, 1993 to 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22712745" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anaphylaxis knowledge among paramedics: results of a national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461139" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931122" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lessons for management of anaphylaxis from a study of fatal reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19927537" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Factors associated with repeated use of epinephrine for the treatment of anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18592821" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Availability of the epinephrine autoinjector at school in children with peanut allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19492662" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epinephrine auto-injectors: first-aid treatment still out of reach for many at risk of anaphylaxis in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159254" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Voluntarily reported unintentional injections from epinephrine auto-injectors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540575" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anaphylaxis in the community: learning from the survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22181034" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The use of adrenaline autoinjectors by children and teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117270" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Food-Allergic Adolescents at Risk for Anaphylaxis: A Randomized Controlled Study of Supervised Injection to Improve Comfort with Epinephrine Self-Injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prospective evaluation of an anaphylaxis education mini-handout: the AAAAI anaphylaxis wallet card</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20392483" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17378256" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fatal anaphylaxis: postmortem findings and associated comorbid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721322" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Allergy and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36654513" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clonal mast cell disorders and hereditaryα-tryptasemia as risk factors for anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23453138" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895993" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347124" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388012" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134576" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19232704" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Accidental allergic reactions in children allergic to cow's milk proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36682535" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Precautionary Allergen Labeling: What Advice Is Available for Health Care Professionals, Allergists, and Allergic Consumers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910035" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Assessment of psychological distress among children and adolescents with food allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19076542" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of peanut allergy on quality of life, stress and anxiety in the family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19560802" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Food allergy and food allergy attitudes among college students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28007086" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Stinging insect hypersensitivity: A practice parameter update 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176256" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565764" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18502492" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608573" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adverse reactions to vaccines practice parameter 2012 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617816" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Food-dependent exercise-induced anaphylaxis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059725" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Food allergen immunotherapy: Current status and prospects for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21913207" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Seminal plasma hypersensitivity reactions: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36371062" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Food Allergy and Eosinophilic Gastrointestinal Diseases-The Next 10 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31025125" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : GRADE-ing the Benefit/Risk Equation in Food Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34979334" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31522849" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283151" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Immunotherapy for Food Allergy: Are We There Yet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31030987" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36204600" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Systematic review of monotherapy with biologicals for children and adults with IgE-mediated food allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36883475" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The next generation virus-like particle platform for the treatment of peanut allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154789" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mast Cells, Mastocytosis, and Related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780942" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mast cell activation syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26968958" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Natural History of Food Allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283158" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Penicillin Allergy Testing Should Be Performed Routinely in Patients with Self-Reported Penicillin Allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36528293" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The Safety of the Direct Drug Provocation Test in Beta-Lactam Hypersensitivity in Children: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36563744" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Penicillin allergy delabeling: Opportunities for implementation and dissemination.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
